secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2025-06-03T23:59:59+00:00
Accession:  0001641172-25-013368
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma presents KROS101 preclinical data at ASCO; shows superiority over TRX518
--------------------------------------------------------------------------------

- KROS101 is a small molecule GITR ligand agonist with dual mechanisms: promotes T effector proliferation and reduces T reg suppression.
- Preclinical study showed KROS101 enhanced T cell cytotoxicity and cytokine production, boosting tumor cell killing.
- KROS101 was superior to anti-GITR antibody TRX518 in T cell tumor infiltration, T reg reduction, and preventing T cell exhaustion.
- CEO Dr. John Yu presented findings at ASCO 2025 (May 30-June 3) and expressed strong support for continued study of KROS101.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000164117225013368/0001641172-25-013368-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000164117225013368/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-013368

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer